Why the study?
Early detection of heart failure has been difficult and prone to misdiagnoses, though monitoring circulatory NT-proBNP levels could enable early risk evaluation.
A novel integrated microfluidic platform enables rapid, low-volume, and highly sensitive detection of NT-proBNP, offering a promising tool for early heart failure diagnosis.
May enable point-of-care NT-proBNP testing in HF; leaves open clinical validation before practice adoption.
Although cardiovascular diseases such as heart failure (HF) affect 30 million people globally, the early detection of HF has, until recently, been difficult and prone to misdiagnoses. Monitoring the circulatory levels of a relatively new biomarker, the N-terminal prohormone of a B-type natriuretic peptide, could be used for early risk evaluation of HF. Therefore, we developed a pneumatically-driven, automatic integrated microfluidic platform equipped with micromixers, micropumps, and microvalves for the simultaneous detection of NT-proBNP in up to six clinical samples within 25 min by using a novel aptamer-based sandwich assay, and the limit of detection was only 1.53 pg mL-1; given that the chip is 64% more compact than those developed in our prior works and requires only 5 μL of sample input, it may serve as a promising tool for early diagnosis of HF.
No takes yet. Share an insight, caveat, or question.
Sinha et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: